Recovery of β-cell functions with low-dose insulin therapy: study in newly diagnosed type 2 diabetes mellitus patients.

Abstract:

AIM:Insulin therapy induces remission in subjects with newly diagnosed type 2 diabetes mellitus (T2DM). This study assessed the insulin and C-peptide levels in newly diagnosed T2DM subjects during low-dose insulin therapy. SUBJECTS AND METHODS:Twenty newly diagnosed, drug-naive, T2DM patients without acute or chronic complications were the subjects for this study. Premixed insulin (70/30), 16 units, as two divided doses, was started for all subjects after preliminary investigations. The same dose of insulin was continued until normoglycemia was achieved. Subsequently the insulin dose was down-titrated. Plasma insulin, C-peptide, and blood glucose (both fasting and after breakfast) were measured at baseline and monthly for 6 months. Body weight and glycosylated hemoglobin (HbA1c) were measured every 3 months and the lipid profile was obtained at baseline and at 6 months. RESULTS:Blood glucose levels showed a rapid decreasing trend and reached the near-normoglycemic range by 3 months, whereas plasma insulin and C-peptide showed a slow and steady increase until the fourth month and remained the same during the next 2 months of follow-up. HbA1c was 11.3 ± 1.4% (range, 8.6-13.5%) and 7.05 ± 0.54% (range, 6.3-8.1%) at the time of diagnosis and at the end of 6 months, respectively. The mean weights of the study subjects at baseline and 3 and 6 months were 70 ± 16 kg (range, 44-95 kg), 68 ± 13 kg, and 68 ± 13 kg (P = 0.083), respectively. Total cholesterol, low-density lipoprotein-cholesterol, and triglycerides decreased, whereas high-density lipoprotein-cholesterol was higher at 6 months. CONCLUSION:Low-dose insulin therapy in newly diagnosed T2DM leads to β-cell recovery (as documented by plasma insulin and C-peptide levels) by 3-4 months.

journal_name

Diabetes Technol Ther

authors

Bhattacharya S,Ammini AC,Jyotsna V,Gupta N,Dwivedi S

doi

10.1089/dia.2010.0187

subject

Has Abstract

pub_date

2011-04-01 00:00:00

pages

461-5

issue

4

eissn

1520-9156

issn

1557-8593

journal_volume

13

pub_type

杂志文章
  • Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects.

    abstract:BACKGROUND:Continuous glucose monitoring is a useful tool for the achievement of improved glucose control in patients with diabetes. We tested the ability of a novel noninvasive continuous glucose monitor to track glucose excursions. METHODS:The novel noninvasive Aprise sensor (Glucon Inc., Boulder, CO) utilizes the p...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2006.0059

    authors: Weiss R,Yegorchikov Y,Shusterman A,Raz I

    更新日期:2007-02-01 00:00:00

  • Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) has been shown to improve glycemic control and reduce hypoglycemia with consistent use. Youth, however, are unlikely to use CGM consistently. We compared psychological characteristics of youth with type 1 diabetes, their parents, and adults with type 1 diabetes randomized ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2011.0201

    authors: Markowitz JT,Pratt K,Aggarwal J,Volkening LK,Laffel LM

    更新日期:2012-06-01 00:00:00

  • Electroencephalography to assess motor control during balance tasks in people with diabetes.

    abstract:BACKGROUND:Balance is sensed through peripheral and central receptors and mediated by central control through the brain and spinal cord. Although some evidence exists as to the areas of the brain involved and how processing of data occurs in young individuals, nothing has been published on people with diabetes. The pur...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2012.0152

    authors: Petrofsky JS,Alshammari F,Lee H,Yim JE,Bains G,Khowailed IA,Deshpande PP,Potnis P,Tse F,Cavalcanti P

    更新日期:2012-11-01 00:00:00

  • Can continuous subcutaneous insulin infusion improve health-related quality of life in patients with Shwachman-Bodian-Diamond syndrome and diabetes?

    abstract::We report the first case of the use of continuous subcutaneous insulin infusion (CSII) in a patient with Shwachman-Bodian-Diamond syndrome (SBDS) and diabetes. An Italian boy received diagnosis of SBDS at the age of 7 months (SBDS gene mutation: c.183-184TA → CT and c.258 + 2 T → C in compound heterozygous). The patie...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2014.0184

    authors: Terlizzi V,Zito E,Mozzillo E,Raia V,Franzese A

    更新日期:2015-01-01 00:00:00

  • Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes.

    abstract:BACKGROUND:There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin pump) therapy in children. METHODS:Charts from 291 youth with type 1 diabetes (T1D) who were treated with CSII therapy for at least 1 year were reviewed. Data analysis included hemoglobin ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2007.0214

    authors: Scrimgeour L,Cobry E,McFann K,Burdick P,Weimer C,Slover R,Chase HP

    更新日期:2007-10-01 00:00:00

  • Measurement Performance of Two Continuous Tissue Glucose Monitoring Systems Intended for Replacement of Blood Glucose Monitoring.

    abstract:BACKGROUND:Currently, two systems for continuous tissue glucose monitoring (CGM) (Dexcom® G5 [DG5] and FreeStyle Libre [FL]) are intended to replace blood glucose monitoring (BGM) and, according to manufacturer labeling, are distributed as such in some jurisdictions, including the United States and the European Union. ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0105

    authors: Freckmann G,Link M,Pleus S,Westhoff A,Kamecke U,Haug C

    更新日期:2018-08-01 00:00:00

  • RETRACTED: No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes.

    abstract::The Editor of Diabetes Technology & Therapeutics is officially retracting the article entitled, "No Deleterious Effect of Lockdown Due to COVID-19 Pandemic on Glycaemic Control, Measured by Glucose Monitoring, in Adults with Type 1 Diabetes," by Beato-Vibora PI. Diabetes Technol Ther 2020; epub DOI: 10.1089/dia.2020.0...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,收录出版

    doi:10.1089/dia.2020.0184

    authors: Beato-Víbora PI

    更新日期:2020-05-12 00:00:00

  • Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve).

    abstract:BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2013.0074

    authors: Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

    更新日期:2013-11-01 00:00:00

  • Interactive educational diabetes/insulin tutorial at www.2aida.info.

    abstract::The World Wide Web now hosts a multitude of diabetes educational materials in various formats. Of particular interest is the diabetes/insulin tutorial available at the AIDA Website (accessible directly at: www.2aida.info). The tutorial combines textual or "static" information with an interactive diabetes simulator-AID...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.126

    authors: Reed K,Lehmann ED

    更新日期:2006-02-01 00:00:00

  • Evaluating rate of change as an index of glycemic variability, using continuous glucose monitoring data.

    abstract:BACKGROUND:There is no consensus as to the best method to assess glycemic variability from continuous glucose monitoring (CGM) data. Rate of change has been suggested as a preferred method of assessing glycemic variability, but this assertion has not been validated. METHODS:Forty-eight hours of CGM data were analyzed ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2010.0215

    authors: Whitelaw BC,Choudhary P,Hopkins D

    更新日期:2011-06-01 00:00:00

  • "Glucometrics"--assessing the quality of inpatient glucose management.

    abstract:BACKGROUND:For patients with diabetes, the quality of outpatient glycemic control is readily assessed by hemoglobin A1c. In contrast, standardized measures for assessing the quality of blood glucose (BG) management in hospitalized patients are lacking. Because of recent studies demonstrating the benefits of strict glyc...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.560

    authors: Goldberg PA,Bozzo JE,Thomas PG,Mesmer MM,Sakharova OV,Radford MJ,Inzucchi SE

    更新日期:2006-10-01 00:00:00

  • Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study.

    abstract:BACKGROUND:This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform s...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2012.0051

    authors: Bergenstal RM,Bode BW,Tamler R,Trence DL,Stenger P,Schachner HC,Fullam J,Pardo S,Kohut T,Fisher WA

    更新日期:2012-10-01 00:00:00

  • Validation of the SoloSTAR insulin pen.

    abstract:BACKGROUND:This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes. METHODS:This single-center, open-label, single-arm, sequential trial enrolled subjects with ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2008.0079

    authors: Schwartz S,Vlajnic A

    更新日期:2008-10-01 00:00:00

  • Physiological and therapeutic roles of peroxisome proliferator-activated receptors.

    abstract::The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor isoforms, including PPARgamma, PPARalpha, and PPARdelta, encoded by different genes. PPARs are ligand-regulated transcription factors that control gene expression by binding to specific response elements (PPREs) within promoters. P...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/15209150260007381

    authors: Berger J,Wagner JA

    更新日期:2002-01-01 00:00:00

  • Continuous glucose monitoring in patients undergoing cardiac surgery.

    abstract:OBJECTIVES:Hyperglycemia is a prominent feature among patients exposed to major stress such as in cardiac surgery. The implementation of a continuous glucose monitoring system (CGMS) for glucose monitoring during cardiac surgery was assessed. SUBJECTS AND METHODS:Fifty-nine consecutive patients who underwent cardiac s...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0154

    authors: Kalmovich B,Bar-Dayan Y,Boaz M,Wainstein J

    更新日期:2012-03-01 00:00:00

  • Continuous glucose monitoring and diabetes health outcomes: a critical appraisal.

    abstract::This paper presents a critical review of continuous glucose monitoring studies that address accuracy, utility in assessing glucose variability, detection of hypoglycemia for improved metabolic control or reduced glucose variability, impact on quality of life, reduced fear of hypoglycemia, and applicability in helping ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2007.0261

    authors: Reach G

    更新日期:2008-04-01 00:00:00

  • Efficacy and safety performance of the Innovo insulin doser.

    abstract::Innovo (Novo Nordisk A/S, Hillerød, Denmark) is a new insulin injection system that offers built-in memory and a large, clear display to provide patients with more control during insulin injections. The aim of this trial was to compare the efficacy and safety of Innovo and NovoPen 3 (Novo Nordisk A/S) in patients expe...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1089/152091504322783413

    authors: Valk NK,Cerny G,Sieber J,Lytzen L,Berg B

    更新日期:2004-02-01 00:00:00

  • Evaluation of a Nurse-Managed Insulin Infusion Protocol.

    abstract:BACKGROUND:The purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND METHODS:This was a retrospective observational cohort study including patients for whom the protocol was order...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2015.0046

    authors: Passarelli AJ,Gibbs H,Rowden AM,Efird L,Zink E,Mathioudakis N

    更新日期:2016-02-01 00:00:00

  • Effectiveness of Automated Insulin Management Features of the MiniMed® 640G Sensor-Augmented Insulin Pump.

    abstract:BACKGROUND:Automated insulin management features of the MiniMed® 640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values ("suspend before low"), suspension in response to existing low SG values ("suspend on low"), and automatic restarting of basal insulin delivery up...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2016.0216

    authors: Zhong A,Choudhary P,McMahon C,Agrawal P,Welsh JB,Cordero TL,Kaufman FR

    更新日期:2016-10-01 00:00:00

  • Use of an insulin bolus advisor facilitates earlier and more frequent changes in insulin therapy parameters in suboptimally controlled patients with diabetes treated with multiple daily insulin injection therapy: results of the ABACUS trial.

    abstract:BACKGROUND:We assessed the impact of using an automated bolus advisor integrated into a blood glucose meter on the timing and frequency of adjusting insulin therapy parameter settings and whether the availability of this technology would increase blood glucose test strip utilization in diabetes patients treated with mu...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2013.0280

    authors: Cavan DA,Ziegler R,Cranston I,Barnard K,Ryder J,Vogel C,Parkin CG,Koehler W,Vesper I,Petersen B,Schweitzer MA,Wagner RS

    更新日期:2014-05-01 00:00:00

  • Daily glucose profiles in Japanese people with normal glucose tolerance as assessed by continuous glucose monitoring.

    abstract:BACKGROUND:Little information is available regarding glucose fluctuations in postprandial states and during the oral glucose tolerance test (OGTT) in Japanese people with normal glucose tolerance (NGT). METHODS:Glucose profiles of 27 Japanese people were measured for 4 days by using continuous glucose monitoring. A 75...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0083

    authors: Tsujino D,Nishimura R,Taki K,Miyashita Y,Morimoto A,Tajima N

    更新日期:2009-07-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses.

    abstract:BACKGROUND:This exploratory study examined the pharmacokinetics and pharmacodynamics of a Bentley Pharmaceuticals, Inc. (North Hampton, NH) proprietary insulin formulation utilizing CPE-215 technology designed for intranasal administration. METHODS:Eight fasting healthy volunteers (four men, four women; body mass inde...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2005.7.124

    authors: Leary AC,Stote RM,Breedt HJ,O'Brien J,Buckley B

    更新日期:2005-02-01 00:00:00

  • Continuous glucose monitoring reveals delayed nocturnal hypoglycemia after intermittent high-intensity exercise in nontrained patients with type 1 diabetes.

    abstract:OBJECTIVE:Exercise is a cornerstone of diabetes therapy in type 1 diabetes mellitus (DMT1) patients. The type of exercise is important in determining the propensity to hypoglycemia. We assessed, by continuous glucose monitoring (CGM), the glucose profiles during and in the following 20h after a session of two different...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1089/dia.2010.0038

    authors: Maran A,Pavan P,Bonsembiante B,Brugin E,Ermolao A,Avogaro A,Zaccaria M

    更新日期:2010-10-01 00:00:00

  • Development of a Collaborative Algorithm for the Management of Type 2 Diabetes during Ramadan: An Anchor on Empowerment.

    abstract::Empowerment plays significant roles in the complex management of type 2 diabetes. International guidelines have provided recommendations on management of Muslims who fast during Ramadan. However, there remains a lack of patient-centered epistemic tool to empower healthcare providers and patients in managing diabetes d...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2018.0159

    authors: Lum ZK,See Toh WY,Lim SM,Rusli KDB,Abdul Shakoor SAKK,Tsou KYK,Chew DEK,Dalan R,Kwek SC,Othman N,Lian JX,Lee JY

    更新日期:2018-10-01 00:00:00

  • Continuous Subcutaneous Insulin Infusion in Neonates and Infants Below 1 Year: Analysis of Initial Bolus and Basal Rate Based on the Experiences from the German Working Group for Pediatric Pump Treatment.

    abstract:BACKGROUND:Diabetes mellitus is rare in young infants and neonates. Continuous subcutaneous insulin infusion (CSII) is used most frequently for insulin treatment in this age group. However, the individual doctor's experience is scarce because of the low prevalence of diabetes in this age. For this study patients treate...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2015.0030

    authors: Kapellen TM,Heidtmann B,Lilienthal E,Rami-Merhar B,Engler-Schmidt C,Holl RW

    更新日期:2015-12-01 00:00:00

  • Effectiveness of virtual reality using video gaming technology in elderly adults with diabetes mellitus.

    abstract:BACKGROUND:Diabetes in elderly adults is associated with an increased risk of fall. The aim of study was to determine whether a virtual reality exercise (VRE) program would improve balance, strength, gait, and falls efficacy in elderly adults with diabetes. SUBJECTS AND METHODS:Fifty-five subjects with diabetes mellit...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2013.0050

    authors: Lee S,Shin S

    更新日期:2013-06-01 00:00:00

  • The effect of local subcutaneous delivery of vascular endothelial growth factor on the function of a chronically implanted amperometric glucose sensor.

    abstract::The foreign body capsule that forms around implanted devices such as glucose sensors is hypovascular and has limited permeability to glucose. Such a capsule may function better if well vascularized. We hypothesized that capsular vascularization achieved by local release of vascular endothelial growth factor (VEGF) wou...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091504773731320

    authors: Ward WK,Wood MD,Casey HM,Quinn MJ,Federiuk IF

    更新日期:2004-04-01 00:00:00

  • Neural network-based real-time prediction of glucose in patients with insulin-dependent diabetes.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) technologies report measurements of interstitial glucose concentration every 5 min. CGM technologies have the potential to be utilized for prediction of prospective glucose concentrations with subsequent optimization of glycemic control. This article outlines a feed-forwar...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0104

    authors: Pappada SM,Cameron BD,Rosman PM,Bourey RE,Papadimos TJ,Olorunto W,Borst MJ

    更新日期:2011-02-01 00:00:00

  • The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.

    abstract::Measuring the hemoglobin A(1c) (HbA(1c)) is the standard-of-care method to assess long-term glycemic control of patients with diabetes, describing the average glycemic level. However, the HbA(1c) does not reflect acute fluctuations in glucose levels. Variability of glycemia probably has an impact on the development of...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0119

    authors: Thomas A,Schönauer M,Achermann F,Schnell O,Hanefeld M,Ziegelasch HJ,Mastrototaro J,Heinemann L

    更新日期:2009-06-01 00:00:00

  • The influence of environmental temperature on the response of the skin to local pressure: the impact of aging and diabetes.

    abstract:BACKGROUND:To protect against ischemia, pressure-induced vasodilation (PIV) causes an increase in skin blood flow. Endothelial dysfunction, which is commonly found in older patients and those with diabetes, and global temperatures can affect the resting blood flow in skin, which may reduce the blood flow during and aft...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0097

    authors: McLellan K,Petrofsky JS,Zimmerman G,Lohman E,Prowse M,Schwab E,Lee S

    更新日期:2009-12-01 00:00:00